Track topics on Twitter Track topics that are important to you
NEW YORK CITY (dpa-AFX) - Atomwise Inc. announced an evaluation agreement with Pfizer Inc. (PFE). Pfizer will evaluate Atomwise's platform to identify potential drug candidates for up to three tar...
Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer. In the agreement, Pfizer will pay a technology access The post Pfi...
Atomwise, Inc., a leader in using artificial intelligence (AI) for drug screening and design, is now accepting applications for their 2018 Artificial Intelligence Molecular Screen (AIMS) awards. The a...
Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. (NYSE: PFE). Pfizer will evaluate ...
The post Atomwise Expands its Groundbreaking Artificial Intelligence Screening Program to Support Academic Projects Worldwide appeared first on SynBioBeta.
Pfizer News: Alopecia Drugs Show Promise, and Company Inks Deal with Atomwise http://dlvr.it/QkTW0S pic.twitter.com/sPefia694a
Pfizer announced results from its Phase IIa clinical trial of PF-06651600 and PF-06700841 in alopecia areata (AA).
Atomwise uses artificial intelligence to help discover new medicines and agricultural compounds. Its groundbreaking AtomNet technology reasons like a human chemist, using powerful...
We have published hundreds of Atomwise Inc. news stories on BioPortfolio along with dozens of Atomwise Inc. Clinical Trials and PubMed Articles about Atomwise Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Atomwise Inc. Companies in our database. You can also find out about relevant Atomwise Inc. Drugs and Medications on this site too.
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...